Risk Factors and Timing of Relapse after Allogeneic Transplantation in Pediatric ALL: For Whom and When should Interventions be Tested?

Podobne zapisy

• The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial
  od: Pulsipher, Michael A., i wsp.
  Wydane: (2014)
• IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
  od: Pulsipher, Michael A., i wsp.
  Wydane: (2015)
• A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)
  od: Pulsipher, Michael A., i wsp.
  Wydane: (2009)
• Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation
  od: Goyal, Rakesh K., i wsp.
  Wydane: (2012)
• Children’s Oncology Group’s 2013 Blueprint for Research: Stem Cell Transplantation
  od: Grupp, Stephan A., i wsp.
  Wydane: (2012)